Literature DB >> 21607046

Bolus fluorouracil induced syncope and pulseless ventricular tachycardia: a case report.

E Fidan, S Fidan, B Yildiz, I Durmus, H Kavgaci, F Ozdemir, F Aydin.   

Abstract

5-fluorouracil is an anti-cancer drug commonly used in oncology practice. Typical side effects are myelosupression, nausea, vomiting, diarrhea and stomatitis. Cardiotoxicity is the other toxicity. Cardiac side effects are ST segment changes, rhythm abnormalities, supraventricular and ventricular dysrhytmias. Pulseless ventricular tachycardia and ventricular fibrillation releated with bolus fluorouracil were not detected in the literature. Here we discussed a 46 year-old male patient that has no known cardiac history. After bolus fluorouracil administration, syncope and pulseless ventricular tachycardia developed in this patient. There are a few explanations about the cardiotoxicity of fluorouracil. One of these is the effect on nitric oxide. It causes a reduction in the levels of endothelial NO and this leads coronary vasospasm. Another explanation is protein kinase C mediated vasospasm. In animal studies toxic myocarditis like lesions were detected with fluorouracil infusions. Finally both myocardit and vasospasm may lead cardiac problems like sudden cardiac deaths. Bolus 5-fluorouracil is as cardiotoxic as 5-fluorouracil infusion and we must be careful about the arrhytmia after the bolus administration.

Entities:  

Keywords:  arrhythmia; cardiac; fluorouracil

Year:  2011        PMID: 21607046      PMCID: PMC3093156     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  7 in total

1.  Cardiotoxicity of 5-flourouracil: two case reports.

Authors:  A Tutkun; S Inanli; O Caymaz; E Ayanoğlu; D Duman
Journal:  Auris Nasus Larynx       Date:  2001-04       Impact factor: 1.863

2.  A case of acute myocardial infarction during 5-fluorouracil infusion.

Authors:  Maria Laura Canale; Andrea Camerini; Stefano Stroppa; Romana Prosperi Porta; Paolo Caravelli; Mario Mariani; Alberto Balbarini; Sergio Ricci
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2006-11       Impact factor: 2.160

3.  Acute heart failure after treatment with 5-fluorouracil.

Authors:  S Georgieva; E Kinova; V Iordanov; A Gudev; V Tzekova; M Velikova
Journal:  J BUON       Date:  2007 Jan-Mar       Impact factor: 2.533

4.  Cardiac lesions induced by 5-fluorouracil in the rabbit.

Authors:  P Tsibiribi; C Bui-Xuan; B Bui-Xuan; C Lombard-Bohas; S Duperret; M Belkhiria; A Tabib; G Maujean; J Descotes; Q Timour
Journal:  Hum Exp Toxicol       Date:  2006-06       Impact factor: 2.903

5.  Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers.

Authors:  Ilhan Oztop; Murat Gencer; Taha Okan; Arzu Yaren; Emel Altekin; Sonay Turker; Ugur Yilmaz
Journal:  Jpn J Clin Oncol       Date:  2004-05       Impact factor: 3.019

Review 6.  Cardiotoxicity of 5-fluorouracil.

Authors:  P Alter; M Herzum; M Soufi; J R Schaefer; B Maisch
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2006-01

7.  Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.

Authors:  Christos Kosmas; Manolis S Kallistratos; Petros Kopterides; John Syrios; Helias Skopelitis; Nicolaos Mylonakis; Athanasios Karabelis; Nicolas Tsavaris
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.322

  7 in total
  1 in total

1.  Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use.

Authors:  Kyoung-Yoon Kim; Bo-Rim Yi; Hye-Rim Lee; Nam-Hee Kang; Eui-Bae Jeung; Seung U Kim; Kyung-Chul Choi
Journal:  Int J Oncol       Date:  2011-12-08       Impact factor: 5.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.